{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:25:50Z","timestamp":1758273950833,"version":"3.41.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale<\/jats:title>\n            <jats:p>Acute promyelocytic leukemia is a special subtype of acute myeloid leukemia. The incidence of early death and complications is high. An oral regimen of all-trans retinoic acid combined with the realgar-indigo naturalis formula (RIF) without chemotherapy has provided a new strategy for the treatment of these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns<\/jats:title>\n            <jats:p>A 92-year-old male patient was admitted to the hospital due to fatigue and oral bleeding. He had no fever or lung infection. Routine blood test showed white blood cell count 1.0\u200a\u00d7109\/L, hemoglobin 100\u200ag\/L, and platelets 21\u200a\u00d7\u200a10<jats:sup>9<\/jats:sup>\/L. Coagulation function indicated fibrinogen 1.02\u200ag\/L and D-dimer 2360\u200ang\/mL. And 28% abnormal promyelocytes were observed in peripheral blood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis<\/jats:title>\n            <jats:p>A bone marrow morphologic, immunophenotypic, cytogenetic, and molecular examination was performed. Routine bone marrow examination showed active proliferation of nucleated cells, with promyelocytes accounting for 91%; immunophenotyping revealed an early myeloid cell population, accounting for approximately 82.4% of all cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions<\/jats:title>\n            <jats:p>From February 15, 2020, 25\u200amg\/m<jats:sup>2<\/jats:sup> all-trans retinoic acid was orally administered daily. After the fusion gene result was obtained, oral administration of 60\u200amg\/kg RIF daily began since February 18, 2020. The combination of the 2 agents was given until March 16, 2020. Oral administration of 25\u200amg\/m<jats:sup>2<\/jats:sup> retinoic acid daily began from March 20, 2020 for 2\u200aweeks, and oral administration of 60\u200amg\/kg RIF daily lasted for 4\u200aweeks as the consolidation therapy. During the treatment, the proportion of promyelocytes in peripheral blood, white blood cell count, platelets, coagulation function, liver function, and QT interval were monitored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes<\/jats:title>\n            <jats:p>Oral retinoic acid and oral RIF were given without chemotherapy and the patient achieved bone marrow remission after 1\u200amonth, and molecular remission was achieved 2\u200amonths later. In the early stage of acute promyelocytic leukemia, combined thrombocytopenia and disseminated intravascular coagulation may develop. Platelet and fresh frozen plasma infusion were proactively given until platelets were stabilized above 30\u200a\u00d7\u200a10<jats:sup>9<\/jats:sup>\/L, and the coagulation function returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons<\/jats:title>\n            <jats:p>The regimen was safe and effective, and subsequent treatment did not require hospitalization, which helped to improve the patient's quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026144","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:12:46Z","timestamp":1622851966000},"page":"e26144","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Successful treatment of acute promyelocytic leukemia in a 92-year-old man using all-trans retinoic acid combined with oral arsenic"],"prefix":"10.1097","volume":"100","author":[{"given":"Xiaowei","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJMe1304762","article-title":"Targeting agents alone to cure acute promyelocytic leukemia","volume":"369","author":"Chen","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20250524","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMc1513710","article-title":"Targeted therapy alone for acute promyelocytic leukemia","volume":"374","author":"Lo-Coco","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"R5-20250524","first-page":"475","article-title":"Chinese Society of Hematology, and C.M.D.A. Chinese Society of Hematologist, [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2014)]","volume":"35","author":"Jun","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi,"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019000760","article-title":"The simpler, the better: oral arsenic for acute promyelocytic leukemia","volume":"134","author":"Zhu","year":"2019","journal-title":"Blood"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12931","article-title":"Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study","volume":"166","author":"Paulson","year":"2014","journal-title":"Br J Haematol"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"key":"R10-20250524","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/s41375-020-0758-4","article-title":"Outcome of older (>\/=70\u200ayears) APL patients frontline treated with or without arsenic trioxide\u2014an International Collaborative Study","volume":"34","author":"Kayser","year":"2020","journal-title":"Leukemia"},{"key":"R11-20250524","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.leukres.2014.06.011","article-title":"Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States","volume":"38","author":"Rashidi","year":"2014","journal-title":"Leuk Res"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/leu.2015.188","article-title":"Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"key":"R13-20250524","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ejh.13018","article-title":"Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia","volume":"100","author":"Cui","year":"2018","journal-title":"Eur J Haematol"},{"key":"R15-20250524","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41375-019-0589-3","article-title":"Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial","volume":"34","author":"Cicconi","year":"2020","journal-title":"Leukemia"},{"key":"R16-20250524","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2146\/ajhp080342","article-title":"Arsenic trioxide as first-line treatment for acute promyelocytic leukemia","volume":"66","author":"Leu","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R17-20250524","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"R18-20250524","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jgo.2020.03.019","article-title":"Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force","volume":"11","author":"Klepin","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"R19-20250524","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bjh.13809","article-title":"Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid","volume":"174","author":"Zhu","year":"2016","journal-title":"Br J Haematol"},{"key":"R20-20250524","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(suppl 2)","key":"R21-20250524","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open issues on bleeding and thrombosis in acute promyelocytic leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thromb Res"},{"key":"R23-20250524","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","article-title":"Management of patients with acute promyelocytic leukemia","volume":"32","author":"Kayser","year":"2018","journal-title":"Leukemia"},{"key":"R24-20250524","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"R25-20250524","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T17:12:02Z","timestamp":1748106722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026144"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":23,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026144","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"2021-02-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}